Ergoteles’s Eterna Therapeutics ERNA Stock Holding History

Ergoteles’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19	Closed	-$75K	–	1661
2022 Q2	$75K	Buy	+19	New	+$136K	﹤0.01%	1540

Other funds holding ERNA

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's ERNA Position: Q3 2022 in Review

Ergoteles sold out of Eterna Therapeutics (ERNA) in Q3 2022, closing a stake of 19 shares — an estimated $75K sold.

Ergoteles first reported a position in ERNA in Q2 2022 and held it in 1 quarter. The position peaked at $75K in Q2 2022. 31 funds tracked by Wall St. Rank hold ERNA as of Q3 2022.

Ergoteles reported no remaining Eterna Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 19 Eterna Therapeutics shares in Q3 2022, an estimated $75K.
Ergoteles first reported a position in Eterna Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Eterna Therapeutics position peaked at $75K in Q2 2022.
31 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.